# OnCo record shr-4849 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/shr-4849/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "shr-4849" ;
  schema:name "SHR-4849"@en ;
  schema:alternateName "IDE849"@en ;
  schema:description "SHR-4849, called IDE849 by IDEAYA Biosciences, is an experimental antibody-drug conjugate aimed at the protein DLL3 in small cell lung cancer and neuroendocrine tumours. Hengrui discovered it and licensed rights outside Greater China to IDEAYA in December 2024."@en ;
  schema:url <https://onco.cc/drugs/shr-4849/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.biospace.com/press-releases/ideaya-biosciences-enters-exclusive-license-with-hengrui-pharma-for-shr-4849-a-novel-phase-1-dll3-topo-i-payload-adc-targeting-sclc-and-net-solid-tumors>, <https://ir.ideayabio.com/2025-09-07-IDEAYA-Biosciences-and-Hengrui-Pharma-Present-Positive-Phase-1-Data-for-IDE849-SHR-4849-,-a-Potential-First-in-Class-DLL3-TOP1-ADC,-in-Small-Cell-Lung-Cancer-at-the-IASLC-2025-World-Conference-on-Lung-Cancer>, <https://clinicaltrials.gov/study/NCT06443489> ;
  onco:status "phase-2" ;
  onco:tag "pipeline", "deal-asset" ;
  onco:modality "Antibody-drug conjugate (DLL3, topoisomerase I inhibitor payload)" ;
  onco:cancers <https://onco.cc/cancers/sclc/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/dll3/> ;
  onco:companies <https://onco.cc/companies/hengrui/>, <https://onco.cc/companies/ideaya-biosciences/> ;
  onco:trials <https://onco.cc/trials/nct07174583/>, <https://onco.cc/trials/nct07028281/>, <https://onco.cc/trials/nct07268040/> .